Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Comment: Pancreatic cancer survival extended by over a year with chemotherapy regimen

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 459

Dr Andrew Epstein and Prof Richard Schilsky

Dr Andrew Epstein and Prof Richard Schilsky comment on data, during a press conference at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, from a phase III randomised trial in which patients with surgically resected pancreatic cancer were treated with mFOLFIRINOX.

For more on these results, watch Dr Conroy present in the press conference here, watch Dr Conroys interview with ecancer here or read the news coverage here.

Related videos

follow us

ONJ e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation